USA – Viiv Healthcare, a specialist HIV company majority-owned by GlaxoSmithKline with Pfizer and Japan’s Shionogi as shareholders, has settled a global patent infringement lawsuit with Gilead Sciences. The case…
Read MoreTag: ViiV Healthcare
FDA approves extended dosing interval for ViiV HIV drug, cutting antiretroviral dosing by half
USA – The U.S. Food and Drug Administration has approved ViiV Healthcare’s HIV treatment Cabenuva for use every two months, which means patients only need to receive an injectable dose…
Read MoreVir expands partnership with Gates Foundation to develop HIV and malaria antibody
USA – Vir Biotechnology and the Bill & Melinda Gates Foundation have collaborated to develop broadly neutralizing antibodies with a vaccinal effect for HIV treatment and malaria prevention. According to…
Read MoreHuge blow to Gilead’s and Merck’s HIV strategy as safety concerns mar once-weekly HIV drug combination
USA – Gilead Sciences, Inc. and Merck have temporarily suspended enrollment in a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir as…
Read MoreViiV Healthcare partners with Japan’s Shionogi to develop longer-acting HIV drug
USA – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK) has agreed to collaborate with Shionogi on the development of ultra-long acting HIV drugs that could…
Read MoreEnhanze drug delivery technology brings ViiV Healthcare and Halozyme into a collaboration
UK – ViiV Healthcare, a global specialist HIV that is majorly owned by GlaxoSmithKline plc have announced a global collaboration and license agreement that gives exclusive access to Halozyme’s ENHANZE…
Read More